Recent Company News

• 02:29 PM ET Apr 14, 2025
  

  Can-Fite announces $3.0M registered direct offering of 2.5M ADSs priced at $1.20/ADS through H.C. Wainwright ($1.60, +0.02)

• 01:42 PM ET Apr 14, 2025
  

  Can-Fite BioPharma ADRs halted; news pending ($1.60, +0.02)

• 08:38 AM ET Apr 14, 2025
  

  Can-Fite anticipates $685M in projected future partnership revenues ($1.57, 0.00)

• 08:06 AM ET Apr 14, 2025
  

  Can-Fite BioPharma reports FY EPS ($0.00) vs year-ago ($0.01) ($1.57, 0.00)

• 09:02 AM ET Mar 24, 2025
  

  Can-Fite BioPharma initiates pivotal Phase 3 psoriasis study of its oral drug Piclidenoson with FDA & EMA-approved protocol ($1.60, 0.00)

• 09:50 AM ET Mar 20, 2025
  

  Can-Fite partner Vetbiolix accelerate Piclidenoson development with advanced clinical trial for canine osteoarthritis ($1.61, -0.02)

• 09:02 AM ET Mar 19, 2025
  

  Can-Fite to initiate Phase II study of Piclidenoson in Lowe Syndrome ($2.02, 0.00)

• 08:34 AM ET Mar 18, 2025
  

  Can-Fite BioPharma receives a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug Namodenoson ($1.65, 0.00)

• 06:19 AM ET Mar 03, 2025
  

  Can-Fite publication: Namodenoson in liver cancer treatment alongside with cardiac, liver, and neurological benefits ($1.76, 0.00)

• 07:10 AM ET Feb 18, 2025
  

  Can-Fite BioPharma announced the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson ($1.53, 0.00)